Table 1.
Baseline characteristics of participants and prescribed cannabis-based medicinal products
| Missing | |||
|---|---|---|---|
| Age in years | Mean (sd) | 37.0 years (11.5) | N = 0 |
| BMI | Mean (sd) | 26.9 kg/m2 (7.4) | N = 22 |
| Charlson comorbidity index | Median (IQR) | 0 (0 to 0) | N = 0 |
| N (%) | |||
| Gender | Male | 207 (68.6%) | N = 0 |
| Female | 95 (31.5%) | ||
| Tobacco use | Current | 117 (38.7%) | N = 0 |
| Previous | 114 (37.8%) | ||
| Never | 71 (23.5%) | ||
| Cannabis use | Current | 188 (62.3%) | N = 0 |
| Previous | 72 (23.8%) | ||
| Never | 42 (13.9%) | ||
| Alcohol use | Yes | 164 (54.3%) | N = 0 |
| No | 138 (45.7%) | ||
| Concurrent medication | Any antidepressant | 161 (53.3%) | N = 0 |
| SSRI | 111 (36.7%) | ||
| Benzodiazepine or Z-drug | 61 (20.2%) | ||
| Gabapentinoid | 19 (6.3%) | ||
| Beta-blocker | 33 (10.9%) | ||
| Substance use frequency (in current users only) | |||
| Cannabis gram per day use | Median (IQR) | 1.0 (0.5 to 2.0) | N = 0 |
| Alcohol intake in units weekly | Median (IQR) | 0.0 (0.0 to 6.0) | N = 0 |
| Smoking pack years | Median (IQR) | 10.0 (2.0 to 21.0) | N = 0 |
| Psychometric questionnaire baseline scores | |||
| GAD-7 | Median (IQR) | 14.0 (9.0 to 18.0) | N = 0 |
| SQS | Median (IQR) | 3.0 (2.0 to 6.0) | N = 1 |
| EQ5D-5L index value | Median (IQR) | 0.58 (0.32 to 0.74) | N = 1 |
| Cannabis-based medicinal products used in cohort | |||
| CBMP | Oil | 89 (29.5%) | N = 0 |
| Flower | 139 (46.0%) | ||
| Both | 74 (24.5%) | ||
| Daily CBD dose at baseline | Median (IQR) | 2.0 mg (0.1 to 20 mg) | |
| Daily THC dose at baseline | Median (IQR) | 21.0 mg (19.0 to 40.0 mg) | |
CBD, cannabidiol; CBMP, cannabis-based medicinal product; IQR, interquartile range; sd, standard deviation; THC, delta-9-tetrahydocannabinol